- Indications and Usage Eltrombopag olamine tablets are indicated for the treatment of chronic immune thrombocytopenia (ITP) in adults and pediatric patients 6 years of age and older who have had an insufficient response to previous treatment with corticosteroids, immunoglobulins, or other therapies.
- Dosage and Administration Recommended Dosage: The recommended starting dose for adults and pediatric patients 12 years of age and older is 50 mg once daily. For pediatric patients 6 to 11 years of age, the recommended starting dose is 25 mg once daily. Administration: The tablet should be swallowed whole with water. It should be taken at least 2 hours before or 4 hours after taking antacids or containing polyvalent cations, or consuming dairy products. Dose Modification: The dose should be adjusted based on the patient’s platelet count response. The maximum recommended dose is 75 mg once daily for adults and 50 mg once daily for children 6 to 11 years of age.
- Mechanism of Action Eltrombopag is an orally available, small-molecule antagonist of the thrombopoietin (TPO) receptor. It stimulates megakaryocyte proliferation and differentiation, leading to increased platelet production.
- Safety and Warnings Thrombotic/Thromboembolic Complications: Serious thrombotic or thromboembolic complications, including portal vein thrombosis, have been reported. Hepatotoxicity: Elevations in liver enzymes and bilirubin have been observed. Liver function tests should be monitored regularly. Risk of Neoplasms: Long-term stimulation of the TPO receptor may increase the risk of neoplasia. Bone Marrow Reticulin Fibrosis: Reversible bone marrow reticulin fibrosis has been observed in patients treated with TPO receptor agonists.
- Adverse Reactions and Clinical Research Common Adverse Reactions: The most common adverse reactions include thrombocytopenia, increased liver enzymes, nausea, diarrhea, arthralgia, back pain, and upper respiratory tract infection. Clinical Research: Efficacy was established in multiple clinical trials demonstrating significant increases in platelet counts and reductions in bleeding risk compared to placebo.
- Drug Interactions Polyvalent Cations: Antacids, laxatives, and supplements containing calcium, iron, magnesium, selenium, or zinc can significantly decrease absorption and should be separated by at least 2 hours before or 4 hours after administration. CYP2C8 Inhibitors: Concomitant use with gemfibrozil increases eltrombopag exposure and should be avoided.
- Pharmaceutical Information Composition: The active ingredient is eltrombopag olamine. Appearance: The tablets vary in color depending on the strength and are film-coated. Storage: Store at controlled room temperature and protect from moisture.
Hengqu Herombopag Olamine Tablets
Brand Name: 恒曲 ®（Hengqu®）
Generic Name: Herombopag Olamine
Strength: 2.5 mg per tablet, 7 tablets per blister, 2 blisters per box
Manufacturer: Jiangsu Hengrui Medicine Co., Ltd.
Marketing Authorization Holder: Jiangsu Hengrui Medicine Co., Ltd.
Approval Date in China: June 16, 2021
Registration Number:国药准字 H20210021
Storage: Seal tightly, protect from light, store below 25°C. Keep out of reach of children. Refer to the full package insert for detailed storage specifications.
Price&Cost:Contact Us now for the best price of Herombopag Olamine（Hengqu）
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.